LATEST NEWS
January 8, 2024: ‘Biocytogen enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma‘
More……
Radiance Biopharma’s mission is to develop a pipeline of next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer and other high unmet medical needs.
Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.
RB-201™ is a ‘First-in-class’ fully human Bispecific ADC targeting both HER2 and TROP-2 conjugated with a protease-cleavable linker to monomethyl auristatin E payload. Learn more
RB-203™ is a based on a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more